PDLI - PDL BioPharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
2.56
-0.01 (-0.39%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.57
Open2.55
Bid2.40 x 21500
Ask2.68 x 800
Day's Range2.52 - 2.57
52 Week Range2.25 - 3.55
Volume586,408
Avg. Volume1,268,750
Market Cap372.224M
Beta (3Y Monthly)-0.03
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2016-06-02
1y Target EstN/A
Trade prices are not sourced from all markets
All
News
Press Releases
  • PDL BioPharma Names Edward Imbrogno Vice President of Finance
    PR Newswire11 days ago

    PDL BioPharma Names Edward Imbrogno Vice President of Finance

    INCLINE VILLAGE, Nev. , Oct. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces the appointment of Edward Imbrogno as Vice President of Finance, a new position.  Mr. ...

  • PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference
    PR Newswire23 days ago

    PDL BioPharma to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

    INCLINE VILLAGE, Nev. , Sept. 26, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • PDL BioPharma Announces New $100 Million Stock Repurchase Program
    PR Newswire25 days ago

    PDL BioPharma Announces New $100 Million Stock Repurchase Program

    INCLINE VILLAGE, Nev., Sept. 24, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (PDLI) announces its Board of Directors has authorized a new stock repurchase program to acquire up to $100 million of the Company's common stock.  Purchases may be made in open-market transactions, in block transactions on or off an exchange, in privately negotiated transactions or by other means as determined by PDL's management and in accordance with the regulations of the Securities and Exchange Commission. "We believe this program is an appropriate means to create shareholder value given the current discrepancy between our share price and our book value," said John McLaughlin, Chief Executive Officer of PDL. The timing of purchases and the number of shares repurchased under the new program by PDL will depend on a variety of factors including price, trading volume, corporate and regulatory requirements and market conditions.  Repurchases may also be made under a trading plan under Rule 10b5-1, which would permit shares to be repurchased when PDL might otherwise be precluded from doing so because of self-imposed trading blackout periods or other regulatory restrictions.

  • PR Newswire29 days ago

    SevenSaoi Capital Delivers Letter to the Board of PDL BioPharma

    Expresses Serious Concerns Regarding PDL's Misguided Acquisition Strategy, Which Has Destroyed Shareholder Value Believes the PDL Board Must Pursue Alternative Capital Allocation Strategies, Including ...

  • PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference
    PR Newswire2 months ago

    PDL BioPharma to Present at the H.C. Wainwright 20th Annual Global Investment Conference

    INCLINE VILLAGE, Nev. , Aug. 30, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) announces that John McLaughlin , PDL's chief executive officer, will ...

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Parker Drilling, CoreLogic, Steven Madden, Diebold Nixdorf, Nevro, and PDL BioPharma — Future Expectations, Projections Moving into 2018

    NEW YORK, Aug. 28, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Parker ...

  • PDL BioPharma Reports Second Quarter 2018 Financial Results
    PR Newswire2 months ago

    PDL BioPharma Reports Second Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , Aug. 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ: PDLI) reports financial results for the three and six months ended June 30, ...

  • ACCESSWIRE2 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 4:30 PM Eastern Time. ...

  • PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products
    PR Newswire3 months ago

    PDL BioPharma Acquires Depomed's Remaining 50% Interest in Royalties and Milestones on Type 2 Diabetes Products

    INCLINE VILLAGE, Nev. , Aug. 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL") (NASDAQ: PDLI) announces an amendment to the Royalty Purchase and Sale Agreement (the "Royalty Agreement") ...

  • PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018
    PR Newswire3 months ago

    PDL BioPharma to Announce Second Quarter Financial Results on August 8, 2018

    INCLINE VILLAGE, Nev. , Aug. 1, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) today announced that the Company will release its second quarter financial ...

  • ACCESSWIRE3 months ago

    Initiating Free Research Reports on Pieris Pharma and Three Other Biotech Equities

    LONDON, UK / ACCESSWIRE / July 18, 2018 / If you want a free Stock Review on PIRS sign up now at www.wallstequities.com/registration. Ahead of today's trading session, WallStEquities.com assesses Pacific Biosciences of California Inc. (NASDAQ: PACB), Paratek Pharmaceuticals Inc. (NASDAQ: PRTK), PDL BioPharma Inc. (NASDAQ: PDLI), and Pieris Pharmaceuticals Inc. (NASDAQ: PIRS).

  • Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors
    PR Newswire4 months ago

    Elizabeth O'Farrell Named to PDL BioPharma's Board of Directors

    INCLINE VILLAGE, Nev. , June 22, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced today that retired Eli Lilly and Company executive Elizabeth ...

  • Shlomo Yanai Elected to PDL BioPharma's Board of Directors
    PR Newswire4 months ago

    Shlomo Yanai Elected to PDL BioPharma's Board of Directors

    INCLINE VILLAGE, Nev. , June 11, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ: PDLI) announced that at its 2018 annual meeting of stockholders held June ...

  • PDL BioPharma Names Dr. Jill Jene Vice President, Business Development
    PR Newswire5 months ago

    PDL BioPharma Names Dr. Jill Jene Vice President, Business Development

    INCLINE VILLAGE, Nev., May 21, 2018 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (PDLI) announces the appointment of Jill M. Jene, Ph.D. as Vice President, Business Development. Dr. Jene will lead the efforts to add healthcare assets to PDL's portfolio of products and companies. She will report to PDL President, Dominique Monnet. "Jill brings to PDL more than 20 years of biopharmaceutical business development experience and an exceptional track-record of success spanning more than $3 billion in licensing and M&A transactions," said Mr. Monnet. "We look forward to her expertise in identifying opportunities and creating novel deal structures that support our goal of increasing shareholder value by expanding our portfolio of biopharmaceutical companies and products.

  • PDL BioPharma to Present at Two Upcoming Investor Conferences
    PR Newswire5 months ago

    PDL BioPharma to Present at Two Upcoming Investor Conferences

    INCLINE VILLAGE, Nev. , May 15, 2018 /PRNewswire/ --   PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the company will present at the following two upcoming investor conferences: UBS Global ...

  • PDL BioPharma Announces First Quarter 2018 Financial Results
    PR Newswire5 months ago

    PDL BioPharma Announces First Quarter 2018 Financial Results

    INCLINE VILLAGE, Nev. , May 9, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today reported financial results for the first quarter ended March 31, 2018 including: Total ...

  • PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018
    PR Newswire6 months ago

    PDL BioPharma to Announce First Quarter 2018 Financial Results on May 9, 2018

    INCLINE VILLAGE, Nev. , May 2, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that it will release its first quarter 2018 financial results for the period ...

  • PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018
    PR Newswire6 months ago

    PDL BioPharma to Hold Annual Meeting of Stockholders on June 8, 2018

    INCLINE VILLAGE, Nev. , April 16, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that the Company will hold its annual meeting of stockholders on Friday, June ...

  • PR Newswire6 months ago

    PDL BioPharma Shareholder, SevenSaoi Capital, Comments on the Nomination of Shlomo Yanai to the PDL Board of Directors and Delivers Letter to the Board Outlining Significant Concerns

    CHICAGO, April 9, 2018 /PRNewswire/ -- SevenSaoi Capital, LLC (together with its affiliates, "SevenSaoi," pronounced "7C"), a long-only public equity investment firm that owns 2,590,198 shares of common stock of PDL BioPharma, Inc. (PDLI) ("PDL" or the "Company"), is pleased that, following SevenSaoi's nomination of Shlomo Yanai to the PDL Board, the Company has added Mr. Yanai to its slate of director nominees for PDL's 2018 Annual Meeting. SevenSaoi introduced and nominated Mr. Yanai to the PDL Board as part of a slate of highly-qualified director candidates in March 2018.

  • PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference
    PR Newswire7 months ago

    PDL BioPharma to Present at the H.C. Wainwright Global Life Sciences Conference

    INCLINE VILLAGE, Nev. , April 3, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) (NASDAQ: PDLI) today announced that Peter Garcia , PDL's vice president and chief financial officer, will ...

  • PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results
    PR Newswire7 months ago

    PDL BioPharma Announces Fourth Quarter and Year End 2017 Financial Results

    Total Revenues Increased by 31% in 2017 GAAP EPS Increased 350% and 82% for Q417 and FY 2017, respectively INCLINE VILLAGE, Nev. , March 8, 2018 /PRNewswire/ -- PDL BioPharma, Inc. (PDL or the Company) ...

  • ACCESSWIRE7 months ago

    PDL BioPharma, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / March 8, 2018 / PDL BioPharma, Inc. (NASDAQ: PDLI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 8, 2018, at 4:30 PM Eastern Time. ...